This study aims to assess the safety tolerability, adherence and effectiveness of genistein as an anti-obesity treatment for children and adolescents. The primary goal is determining how well genistein is tolerated and adhered to by pediatric patients with obesity. Secondary goals include evaluating its impact on body mass index z-scores and cardiometabolic risk factors, such as inflammation.
Participants aged 4-18 will be recruited from the Paediatric HEAL (Healthy Eating, Activity & Lifestyle) Program at the Children's Hospital - London Health Science Center in London, Ontario. They will receive genistein treatment over 6 months, with interim assessments at 3 and 6 months to monitor efficacy, safetytolerability, and adherence, and efficacy, and potentially increase the dose at the 3-month visit. A final assessment will occur after a 3-month washout to observe any lasting effects.
Blood and urine samples will be collected to analyze various adherence and health markers, including inflammatory and cardiometabolic factors. For participants who are of childbearing potential and have had their first menses, the blood analysis will also include pregnancy testing. Laboratory testing will be performed at baseline, at three and six months while taking genistein and three months after the washout period. Urine samples will also confirm that genistein has been taken appropriately throughout the study.
The study expects that genistein will be well-tolerated by children, reduce BMI z-scores by 0.2 (0.5), and improve cardiometabolic risk factors such as blood pressure, lipid profiles, and inflammation. A sample size of 60 participants has been calculated to achieve statistically significant results, which will inform more extensive studies on genistein's potential for managing pediatric obesity.

开始日期2025-08-01

申办/合作机构

Western University

[+1]

CTRI/2025/03/083415

/ Not yet recruiting临床2期IIT

Effect of Genistein on Fecal Microbial Diversity, Modified Mayo Score, and Biomarkers in Patients with Ulcerative Colitis: A Placebo-Controlled Study. - NIL

开始日期2025-05-21

申办/合作机构-

NCT06741345

/ Recruiting临床1期

A Phase 1 Multiple Ascending Dose and Food Effect Trial of BIO 300 Oral Suspension in Healthy Volunteers

This is a two-part study of BIO 300 Oral Suspension in healthy male and female volunteers. The first part is a multiple ascending dose (MAD) study to test the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the drug when given as daily doses over 14 days. The study will enroll three cohorts each receiving a different daily dose: 2000 mg, 3000 mg, or 4000 mg. A fourth group may be added depending on results on the first three cohorts. Each cohort will include 10 participants (5 men, 5 women), with at least 8 completing all study steps. Participants will follow a special diet low in soy-based foods and will fast before certain doses. Blood samples and health checks will be done throughout the study to assess safety, drug is absorption and distribution in the body (PK), and its effects (PD). Safety will be reviewed after each group finishes to decide if the next dose level is safe to proceed.
The second part of the study is a food effect study to examine how food effects the PK of a single dose of BIO 300 Oral Suspension. This study will enroll 16 participants (8 men, 8 women) and will be split into two groups: one group will take the drug after fasting for 10 hours and the other will take the drug after eating a high-fat meal. After a 7-day break, participants will switch conditions (the previously fasted group will take the drug with food, and the previously fed group will take the drug after fasting). Blood samples and health checks will measure how food influences drug absorption (PK) and safety. Both the MAD study and food effect study aim to ensure the drug is safe and provide data on how it behaves in the body under different conditions.

开始日期2024-12-23

申办/合作机构

Humanetics Corp.

100 项与 Genistein 相关的临床结果

登录后查看更多信息

100 项与 Genistein 相关的转化医学

登录后查看更多信息

100 项与 Genistein 相关的专利（医药）

登录后查看更多信息

22,874

项与 Genistein 相关的文献（医药）

2025-12-31·Epigenetics

An overview of potential of natural compounds to regulate epigenetic modifications in colorectal cancer: a recent update

Review

作者: Duttaroy, Asim K. ; Philip, Neha ; Pathak, Surajit ; Siripragada, Sravani ; Roy, Susmita ; Deka, Dikshita ; Banerjee, Antara ; Ayyadurai, Pavithra ; Kondaveeti, Suresh Babu

Colorectal cancer (CRC) remains an alarming global health concern despite advancements in treatment modalities over recent decades. Among the various factors contributing to CRC, this review emphasizes the critical role of epigenetic mechanisms in its pathogenesis and progression. This review also describes the potential role of natural compounds in altering the epigenetic landscape, focused mainly on DNA methylation, histone modification, and non-coding RNAs. Publications from the previous five years were searched and retrieved using well-known search engines and databases like PubMed, Google Scholar, and ScienceDirect. Keywords like CRC/colorectal cancer, CAC/Colitis associated CRC, inflammasomes, epigenetic modulation, genistein, curcumin, quercetin, resveratrol, anthocyanins, sulforaphane, and epigallocatechin-3-gallate were used in various combinations during the search. These natural compounds predominantly affect pathways such as Wnt/β-catenin, NF-κB, and PI3K/AKT to suppress CRC cell proliferation and oxidative stress and enhance anti-inflammation and apoptosis. However, their clinical use is restricted due to their low bioavailability. However, multiple methods exist to overcome challenges like this, including but not limited to structural modifications, nanoparticle encapsulations, bio-enhancers, and novel advanced delivery systems. These methods improve their potential as supportive therapies that target CRC progression epigenetically with fewer side effects. Current research focuses on enhancing epigenetic targeting to control CRC progression while minimizing side effects, emphasizing improved specificity, bioavailability, and efficacy as standalone or synergistic therapies.

2025-12-31·Journal of the International Society of Sports Nutrition

Survey of nutritional intake status in college baseball players

Article

作者: Aoyama, Yuka ; Tanaka, Mamoru ; Seguchi, Manato ; Iio, Yoko ; Kozai, Hana ; Mori, Yukihiro ; Ito, Morihiro

BACKGROUND:

Diet is closely related to exercise performance. To improve athletes' performance and manage their condition, it is important to get sufficient energy and various nutrients. Thus, it is necessary that athletes understand their nutritional intake status to improve performance and maintain health. This study aimed to explore the nutritional intake status of college baseball players using the Food Frequency Questionnaire (FFQ). Furthermore, the characteristics of their nutritional intake status with respect to athletic performance were evaluated. The result of this studyprovide an opportunity for many under-developed college athletes with irregular lifestyles to recognize and improve their nutritional problems.

METHODS:

In October 2022, a questionnaire survey of 116 male members of a college baseball club was conducted. Of whom, 100 (94.3%) members responded to the survey and 92 (92.0%) provided valid responses. The survey items included basic characteristics such as college grade and type of living arrangement, and information on living conditions, e.g. whether the participant ate breakfast. Nutritional intake was evaluated using the FFQ. Players were divided into the first (regular players in official games), second (bench players in official games), third (players who may join the second or higher team in the future), and fourth teams (players who do not belong to the first to third teams); these categories were used as a marker of performance level. The Kruskal-Wallis test was used to analyze the association between the performance levels of baseball players and the intake of each nutrient and food group obtained by the FFQ. For items that showed a significant association, inter-group comparison was performed using the Dunn-Bonferroni method.

RESULTS:

Carbohydrate intake was greater in the second team compared with the third and fourth teams; saturated and monounsaturated fatty acid intake was higher in the third team compared with the fourth team. Calcium, zinc, copper, manganese, insoluble dietary fiber, iodine, and molybdenum intake was higher in the second team compared with the fourth team. Intake of grains, sugar, dairy, and total energy was significantly higher in the second team compared with the fourth team. However, the protein intake ratio was significantly lower in the second team compared with the fourth team. Overall, energy deficiency and associated deficiencies in protein, fat, and carbohydrate were observed, in addition to dietary fiber and calcium deficiencies. The intake of several food groups appeared inadequate, such as potatoes, beans, vegetables, fruits, eggs, milk, and fats.

CONCLUSIONS:

The study showed deficiencies in the amount of energy and nutrients such as protein, fat, and carbohydrate in college baseball players. Differences in the intake of carbohydrate, calcium, and insoluble dietary fiber among different performance levels were observed, with significantly higher intake of carbohydrate, calcium, and insoluble dietary fiber in the second team. Implementing organized and strategic remedial measures and athletes' identification of nutritional problems are vital to overcome nutritional and energy deficiencies. This study provides useful information for the development of strategies to support nutritional intake in college baseball players.

2025-12-31·GM Crops & Food-Biotechnology in Agriculture and the Food Chain

Functional analysis of type II chalcone isomerase ( CHI ) genes in regulating soybean ( Glycine max L .) nodule formation

Article

作者: Wang, Qingyu ; Zhou, Yuxue ; Liu, Yajing ; Yang, Xuguang ; Wang, Le ; Wang, Xinyue ; Han, Hongshuang ; Zhang, Jinhao ; Wang, Ying ; Li, Jingwen

Biological nitrogen fixation (BNF) is the most cost-effective and environmentally benign method for nitrogen fertilization. Isoflavones are important signaling factors for BNF in leguminous plants. Whether chalcone isomerase (CHI), the key enzyme gene in the flavonoid synthesis pathway, contributes to soybean (Glycine max) nodulation has not yet been fully clarified. In the present study, we identified the functions of three types of GmCHI for BNF using a hairy root system. The results showed that GmCHI1A and GmCHI1B1 positively increased nodulation while GmCHI1B2 did not, with the GmCHI1A gene having a greater effect than GmCHI1B1. Meanwhile, the daidzein and genistein contents were significantly increased in composite plants overexpressing GmCHI1A and reduced in composite plants, thus interfering with GmCHI1A. However, overexpression of GmCHI1B1 significantly increased the content of glycitein but not daidzein, genistein content implied that homologous genes exhibit functional differentiation. These results provide a reference for subsequent studies on improving nitrogen fixation in soybeans and providing functional genes for the improvement of new varieties.

项与 Genistein 相关的新闻（医药）

2025-03-17

·GlobeNewswire-Health Care

Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome

Humanetics’ Novel Radioprotective Agent Being Developed with Funding from Department of Defense as Radiation Medical Countermeasure (MCM) Lifecore to Carry Out Tech Transfer and Analytical Method Activities, including Filling of Pilot Batch CHASKA, Minn. and MINNEAPOLIS, March 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and Humanetics Corporation (“Humanetics”), an advanced clinical-stage pharmaceutical company, today announced that Humanetics has selected Lifecore to provide a range of CDMO services to support the continued development of BIO 300 for the prevention of acute radiation syndrome. Under the terms of the agreement, Lifecore will conduct technology transfer of the existing fill and finish process for BIO 300, including formulation development, gap assessment, and filling of a pilot batch. Lifecore will also undertake analytical method work including feasibility assessments designed to estimate future development work for the product candidate. “This relationship represents another important example of the momentum that we are generating at Lifecore as we execute against our strategic growth plan. Humanetics’ BIO 300 is the exact type of promising, cutting-edge biopharmaceutical product that we strive to support, and we are gratified to have been selected by the company to provide these services,” said Paul Josephs, chief executive officer of Lifecore. “Additionally, this collaboration between two Minnesota-based life science companies helps shine a spotlight on the impressive medical innovation that is coming out of our state, and we are thrilled to be able to support the important work being advanced by Humanetics.” “We are excited about working with Lifecore in our own backyard, showcasing the exceptional talent and innovation Minnesota has to offer,” said Ronald Zenk, chief executive officer of Humanetics. “Results of this collaboration will help provide critical protection against exposure to radiation for warfighters, First Responders and civilian populations worldwide.” In addition to the acute radiation syndrome program, BIO 300 is currently in late-stage clinical development for the mitigation of impaired pulmonary function in COVID-19 patients recently discharged from the hospital. Humanetics recently announced promising data from a Phase 2 clinical trial of BIO 300. The compound is also in development for oncology applications to protect cancer patients from unintentional side effects caused by radiation therapy. AcknowledgementThe U.S. Army Medical Research Acquisition Activity, 808 Schreider Street, Fort Detrick MD 21702-5014 is the awarding and administering acquisition office. This work was supported by The Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, in the amount of $5,132,520 through the Peer Reviewed Medical Research Program under Award Number W81XWH-22-1-0516. Opinions, interpretations, conclusions, and recommendations are those of the author(s) and are not necessarily endorsed by The Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense. About Lifecore Biomedical Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com. About Humanetics CorporationHumanetics is an advanced clinical-stage pharmaceutical company engaged in the accelerated discovery, development, and commercialization of proprietary drugs in markets with urgent and unmet needs, with a focus on medical countermeasures, radiation modulators for oncology and inflammatory lung diseases. For more information, visit www.humaneticscorp.com. Important Cautions Regarding Forward-Looking Statements This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements. In addition, all statements regarding our anticipated future operating and financial expectations, customer opportunities and relationships are forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors among others, as the company’s ability to successfully enact its business strategies, including with respect to installation, capacity generation and its ability to attract demand for its services, and its ability expand its relationship with its existing customers or attract new customers; the impact of inflation on Lifecore’s business and financial condition; changes in business conditions and general economic conditions both domestically and globally, including rising interest rates and fluctuation in foreign currency exchange rates; Lifecore’s ability to access sufficient capital to fund its business strategies; and other risk factors set forth from time to time in Lifecore’s SEC filings, including, but not limited to, the Annual Report on Form 10-K for the year ended May 26, 2024 (the “2024 10-K”). For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to our filings with the Securities and Exchange Commission, including the risk factors contained in the 2024 10-K. Forward-looking statements represent management’s current expectations as of the date hereof and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances. Lifecore Biomedical, Inc. Contact Information: Vida Strategic PartnersStephanie Diaz (Investors)415-675-7401sdiaz@vidasp.com Tim Brons (Media)415-675-7402tbrons@vidasp.com Ryan D. Lake (CFO)Lifecore Biomedical952-368-6244ryan.lake@lifecore.com

临床2期放射疗法引进/卖出

2025-02-25

·Business Wire

Humanetics Corporation Chief Medical Officer Is Featured Guest at U.S. Industry, National Security, and Healthcare Forum

MINNEAPOLIS--(BUSINESS WIRE)--Humanetics Corporation, an advanced clinical-stage specialty pharmaceutical company developing radioprotectant drugs for warfighters and patients with cancer and inflammatory lung diseases, today announced that its Chief Medical Officer, Rear Admiral Colin G. Chinn, MD, MHS, FACP (Ret.), will be a featured guest at a private industry, national security, and healthcare forum on February 27, 2025 in Naples, FL, entitled “Advancing America’s Future in Critical Industries.” Dr. Chinn will address “Breakthroughs in Radiation Protection for Military & Healthcare.” About BIO 300 Humanetics is pioneering the development of BIO 300, a groundbreaking radioprotectant drug. This innovative medical countermeasure, which can be used in military and medical contexts, is designed to provide whole-body protection against radiation damage, setting it apart from other drug candidates. BIO 300 has received considerable attention, funding, and research from the Department of Defense (DoD) for its potential to mitigate the harmful effects of radiation among warfighters and civilians in the event of a nuclear attack or radiological incident. The need for such a medical countermeasure has escalated significantly given current world events. Humanetics is currently working under a contract with DoD to approve BIO 300 for use under Emergency Use Authorization to provide prophylactic protection to warfighters across the globe. BIO 300 is also indicated for use as a new class of drug to improve outcomes in cancer patients who received first-line radiotherapy with or without concurrent chemotherapy. These patients suffer myriad side effects that can reduce the efficacy of treatment or result in serious toxicities. BIO 300 selectively protects normal tissue but not cancer tumors, thereby improving therapeutic outcomes. BIO 300 is currently undergoing Phase 2 clinical trials, marking a significant milestone in its development. The trials aim to evaluate its effectiveness in preventing normal tissue injury from cancer radiotherapy and reducing lung damage in COVID-19 long-haul patients (results recently announced). Administered as an oral liquid, BIO 300 has shown potential to minimize radiation damage in normal tissue without compromising the effectiveness of radiation therapy against the tumor. Positive results from the Phase 1b/2a clinical trial in non-small cell lung cancer patients undergoing chemoradiotherapy further bolster BIO 300 prospects, highlighting its safety and potential for positive clinical outcomes. About Humanetics Corporation Humanetics is an advanced clinical-stage pharmaceutical company engaged in the accelerated discovery, development, and commercialization of proprietary drugs in markets with urgent and unmet needs, with a focus on medical countermeasures, radiation modulators for oncology, and inflammatory lung diseases. For more information, visit www.humaneticscorp.com.

放射疗法临床2期

2025-01-22

·Business Wire

Humanetics Corporation Announces Positive Phase 2 Clinical Trial Results in COVID-19 Study Aimed at Improving Pulmonary Function

MINNEAPOLIS--( BUSINESS WIRE )--Humanetics Corporation (Humanetics) announced today the results of its Phase 2 clinical trial of BIO 300 Oral Suspension (BIO 300) for the mitigation of impaired pulmonary function in COVID-19 patients recently discharged from the hospital. BIO 300 is an oral drug that patients self-administer daily for 12 weeks following hospital discharge. The study compared the lung function, exercise capacity, and quality of life in COVID-19 survivors who received BIO 300 against a placebo group. The trial enrolled 38 participants across multiple U.S. sites ( NCT04482595 ). Rany Condos, MD, a clinical Professor in the Department of Medicine at NYU Grossman School of Medicine and Director of its Post-COVID Program, served as the lead investigator. Patients previously hospitalized with COVID-19 complications and discharged with residual lung complications (e.g., long COVID) were eligible if enrolled within two years of discharge. Multiple pulmonary function assessments and a patient-reported quality of life questionnaire were used to evaluate BIO 300’s efficacy. Although the study fell short of its planned enrollment of 50 participants, the 20 BIO 300-treated participants within the enrolled cohort of 38 exhibited improved lung function and participant-reported quality of life compared to placebo-treated participants. Key Trial Findings: Improvement in Pulmonary Function: Participants who received BIO 300 demonstrated a statistically significant improvement in pulmonary function at 12 weeks, which was maintained at 12 months, as measured by forced expiratory volume in one second (FEV1). Additionally, clear statistical trends for improved pulmonary function were observed in BIO 300-treated participants at 12 weeks, 6 months, and 12 months, as measured by the diffusing capacity of the lung for carbon monoxide (DLCO) and forced vital capacity (FVC). Quality of life: Participants treated with BIO 300 showed a clear trend toward an improved quality of life as measured by the St. George’s Respiratory Questionnaire at 6 months, which was maintained at 12 months. Safety Profile: BIO 300 treatment was well-tolerated, with adverse events consistent with those expected in this patient population. No new safety concerns were identified during the trial. "We are highly encouraged by the results of this clinical trial, particularly the promising trends in pulmonary function improvement among COVID-19 participants treated with BIO 300," said Michael Kaytor, PhD, Vice President of Research and Development at Humanetics. "We are continuing to evaluate the data to refine our understanding of BIO 300’s efficacy in COVID-19 and its potential applications for improving patient outcomes." BIO 300 is also in development as a medical countermeasure for use by the United States Department of Defense and for oncology applications to protect patients from side effects caused by radiation. "As BIO 300 has been shown to mitigate inflammation of the lungs and pulmonary fibrosis caused by radiation, we believe that the same effect can be shown in COVID-19 patients,” said Ronald J. Zenk, Chief Executive Officer at Humanetics. “We are optimistic that this treatment could be a valuable addition to the ongoing efforts to combat long COVID and other conditions with lung inflammation and are committed to evaluating its impact in future studies.” This project was funded by the National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health, Department of Health and Human Services, under Contract HHSN272201800011C. About Humanetics Corporation Humanetics is an advanced clinical-stage pharmaceutical company engaged in the accelerated discovery, development, and commercialization of proprietary drugs in markets with urgent and unmet needs, with a focus on medical countermeasures, radiation modulators for oncology and inflammatory lung diseases. For more information, visit www.humaneticscorp.com .

临床2期临床结果放射疗法

100 项与 Genistein 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11680	Genistein	-	DB01645

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
儿童肥胖	临床2期	-	Western University	2025-08-01
射血分数降低的心力衰竭	临床2期	加拿大	Greenstone Biosciences, Inc.	2024-09-27
转甲状腺素蛋白淀粉样变性心肌病	临床2期	加拿大	Greenstone Biosciences, Inc.	2024-09-27
心脏衰竭	临床2期	斯洛文尼亚	Greenstone Biosciences, Inc.	2024-07-01
肺损伤	临床2期	美国	Humanetics Corp.	2022-04-27
新冠肺炎后遗症	临床2期	美国	Humanetics Corp.	2020-11-11
肺纤维化	临床2期	美国	Humanetics Corp.	2020-11-11
非肌层浸润性膀胱肿瘤	临床2期	美国	National Institutes of Health	2017-05-19
非小细胞肺癌 II期	临床2期	美国	Humanetics Corp.	2015-11-01
晚期恶性实体瘤	临床2期	加拿大	Uman Pharma, Inc.	2012-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01489813 (CTgov)	临床2期	非肌层浸润性膀胱肿瘤	36	sugar pill (Sugar Pill)	窪襯壓餘顧壓構淵鑰顧(遞觸窪顧廠構廠積鏇廠) = 艱鏇獵糧製蓋衊構齋糧築網廠齋艱憲襯衊簾淵 (簾淵選製網艱窪顧廠遞, 齋蓋窪鹹蓋夢選夢構築 ~ 製襯願夢獵遞鹹壓製獵) 更多	-	2024-07-25
				Genistein (Genistein Supplement)	窪襯壓餘顧壓構淵鑰顧(遞觸窪顧廠構廠積鏇廠) = 築範願選窪鹽齋齋簾衊築網廠齋艱憲襯衊簾淵 (簾淵選製網艱窪顧廠遞, 壓壓齋糧鏇蓋築顧網艱 ~ 鬱簾鏇糧觸積獵鬱鹽積) 更多
EULAR2024	N/A	大动脉炎	-	Genistein	願繭選糧遞構膚鹽膚顧(憲獵壓積築網範鏇構窪) = 憲壓簾鑰簾衊衊膚製鹽膚淵廠夢壓夢壓壓網鏇 (選願憲觸顧憲遞築襯製 )	积极	2024-06-05
NCT02624388 (UVA-Gen001, CTgov)	临床2期	霍奇金淋巴瘤 \| 肾母细胞瘤 \| 儿童恶性实体瘤 ... 更多	4	Placebo+Genistein (Arm A: Genistein Followed by Placebo)	遞願餘願鏇鹽積簾餘鏇(獵廠淵襯積廠鏇糧築鬱) = 範鏇淵齋齋夢繭積鏇鬱鏇廠獵膚範鑰鏇範範艱 (網鑰膚膚憲鑰簾糧選襯, 1.26) 更多	-	2024-05-06
				Placebo+Genistein (Arm B: Placebo Followed by Genistein)	遞願餘願鏇鹽積簾餘鏇(獵廠淵襯積廠鏇糧築鬱) = 鑰窪餘選構鹹夢蓋鏇膚鏇廠獵膚範鑰鏇範範艱 (網鑰膚膚憲鑰簾糧選襯, 2.08) 更多
NCT04650555 (CTgov)	临床1期	急性放射综合征	34	BIO 300 Oral Powder (Single Ascending Dose Cohort 1)	淵顧繭鹹鬱壓糧廠醖窪(蓋鬱構壓窪簾蓋鹹觸廠) = 鑰襯餘夢顧築襯鹹蓋蓋襯衊積衊獵淵廠壓壓齋 (艱憲範積鑰齋壓積築窪, 9.3) 更多	-	2024-05-03
				BIO 300 Oral Powder (Single Ascending Dose Cohort 2)	構選鬱顧襯簾遞壓願製 = 簾鬱壓鏇選遞製積鹹觸製壓構觸襯衊選製顧簾 (廠鏇淵夢襯淵廠餘齋鹽, 壓艱積鑰蓋範廠憲繭鹹 ~ 襯齋獵憲廠艱積醖構鑰) 更多
NCT02567799 (NSCLC, CTgov)	临床1/2期	非小细胞肺癌 II期 \| 非小细胞肺癌	21	BIO (BIO 300 Oral Suspension (500 mg/Day))	窪餘淵顧齋遞醖網構製 = 構淵壓蓋糧鬱糧觸製膚淵蓋艱繭衊襯壓積顧鏇 (憲繭觸憲齋範築積網餘, 範衊範憲醖鏇繭淵壓衊 ~ 繭鬱窪網鹹鬱醖糧積蓋) 更多	-	2023-12-20
				BIO (BIO 300 Oral Suspension (1000 mg/Day))	窪餘淵顧齋遞醖網構製 = 鹹淵蓋鏇範蓋夢顧鬱願淵蓋艱繭衊襯壓積顧鏇 (憲繭觸憲齋範築積網餘, 衊淵簾鹽繭淵醖願選夢 ~ 醖蓋夢齋鹹襯獵膚獵衊) 更多
NCT02567799 (Biospace) 人工标引	临床1/2期	非小细胞肺癌	21	BIO 300	襯齋築鬱顧鏇齋積襯鏇(鏇憲蓋鬱醖壓餘夢網築) = 鹽窪觸蓋齋網範衊鑰製糧鏇壓鏇構鏇廠網齋簾 (鏇窪窪獵醖蓋遞鏇醖醖 ) 更多	积极	2023-09-19
NCT02766478 (GeniPro, CTgov)	临床2期	前列腺癌 \| 代谢性疾病	10	Genistein (Genistein)	鹽鏇鏇窪簾繭齋範窪齋(廠鹹觸衊顧夢鏇構艱觸) = 鑰齋繭獵窪憲鏇窪艱蓋築鹹艱構遞築衊衊網廠 (構獵遞廠願鹽積鏇淵顧, 遞鬱窪鏇鏇蓋齋鬱衊襯 ~ 製獵遞鹹膚艱膚夢壓鹹) 更多	-	2022-09-27
				Placebo (Placebo)	鹽鏇鏇窪簾繭齋範窪齋(廠鹹觸衊顧夢鏇構艱觸) = 廠鏇鏇遞獵鬱築構夢餘築鹹艱構遞築衊衊網廠 (構獵遞廠願鹽積鏇淵顧, 蓋壓蓋餘膚餘鹹範艱獵 ~ 衊夢選窪襯範醖範齋淵) 更多
NCT04650555 (BusinessWire) 人工标引	临床1期	-	34	BIO 300	觸膚願壓鬱積糧齋醖獵(艱淵範遞鏇鏇觸選廠鹽) = increase survival in persons exposed to lethal levels of radiation 衊襯選積鹽積鬱蓋構繭 (艱鹽積襯網衊艱夢築構 )	积极	2021-09-22
NCT01985763 (Pubmed \| Cancer Chemother Pharmacol) 人工标引	临床1/2期	转移性结直肠癌	13	FOLFOX+Bevacizumab+Genistein	醖衊積築衊構襯齋積範(積襯襯觸範顧積繭獵構) = 1patirent (grade 3 hypertension) 膚製衊鏇構齋淵襯顧範 (壓製顧壓艱壓鑰鹽網餘 ) 更多	积极	2019-09-01
NCT00287690 (CTgov)	临床2/3期	冠心病	71	Genistein (Genistein)	鹽選築鬱淵獵構簾齋範(鹹衊鑰繭鹽壓鹹鹽鬱遞) = 夢願鏇構襯遞鏇繭網簾鏇夢襯範鏇衊製齋簾觸 (淵齋顧築憲餘膚遞簾鬱, 0.4) 更多	-	2019-08-05
				Placebo (Placebo)	鹽選築鬱淵獵構簾齋範(鹹衊鑰繭鹽壓鹹鹽鬱遞) = 艱窪鹽製簾蓋繭鹹繭衊鏇夢襯範鏇衊製齋簾觸 (淵齋顧築憲餘膚遞簾鬱, 0.4) 更多